Erectile Dysfunction - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Erectile Dysfunction - Pipeline Review, H2 2019
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 3, 7, 14, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 3, 7, 14, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction - Companies Involved in Therapeutics Development
Aquestive Therapeutics Inc
Astellas Pharma Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
CardioVascular BioTherapeutics Inc
Cure Pharmaceutical Inc
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Hemostemix Inc
Humanetics Corp
Karessa Pharma Holding AB
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
NAL Pharmaceuticals Ltd
Pharmicell Co Ltd
Saniona AB
SK Chemicals Co Ltd
Suda Pharmaceuticals Ltd
Targazyme Inc
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Erectile Dysfunction - Drug Profiles
(finasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGM-175 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-788 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BZ-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ILG-F - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SID-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vardenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vardenafil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yonkenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: New clinical data provide additional validation for the safety and efficacy of Futura Medicals topical MED2005 in the treatment of erectile dysfunction
Oct 21, 2019: Final dosing of last patient in MED2005 phase 3 study
Oct 15, 2019: Futura Medical to present data on MED2005 for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of SMSNA and Host Advisory Meeting
Sep 27, 2019: Initiator Pharma starts dosing of last the patients in the IPED2015 clinical trial
Sep 03, 2019: Initiator Pharma receives commitment of support for IPED2015 from Innovation Fund Denmark
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Erectile Dysfunction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H2 2019
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2019
Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H2 2019
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2019
Erectile Dysfunction - Pipeline by CardioVascular BioTherapeutics Inc, H2 2019
Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, H2 2019
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2019
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2019
Erectile Dysfunction - Pipeline by Hemostemix Inc, H2 2019
Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2019
Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H2 2019
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2019
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2019
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2019
Erectile Dysfunction - Pipeline by Saniona AB, H2 2019
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2019
Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H2 2019
Erectile Dysfunction - Pipeline by Targazyme Inc, H2 2019
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2019
Erectile Dysfunction - Dormant Projects, H2 2019
Erectile Dysfunction - Dormant Projects, H2 2019 (Contd..1), H2 2019
Erectile Dysfunction - Dormant Projects, H2 2019 (Contd..2), H2 2019
Erectile Dysfunction - Discontinued Products, H2 2019
List Of Figures
Number of Products under Development for Erectile Dysfunction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
RELATED REPORTS
COVID-19 Outbreak-Global Erectile Dysfunction Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
Erectile Dysfunction (impotence) is the inability to get and keep an erection firm enough for sex.Male sexual arousal is a complex process that involves the brain, hormones, emotions, nerves, muscles
View ReportDrugs For Erectile Dysfunction Global Market Report 2020
Drugs For Erectile Dysfunction Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global drugs
View ReportCOVID-19 Outbreak-Global Erectile Dysfunction Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
Erectile Dysfunction (impotence) is the inability to get and keep an erection firm enough for sex.Male sexual arousal is a complex process that involves the brain, hormones, emotions, nerves, muscles
View ReportMeibomian Gland Dysfunction - Market Insight, Epidemiology and Market Forecast - 2030
Meibomian Gland Dysfunction - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Meibomian Gland Dysfunction, historical and forecasted epidemiology as well as the Meibomian Gland
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
